Cabazitaxel: Evidence and clinical experience

British Journal of Medical and Surgical Urology

Volumn 4, Issue SUPPL. 1, 2011, Pages

  Malik, Zafar Iqbal ^a  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

Abiraterone; Cabazitaxel; Castrate resistant prostate cancer; Docetaxel; Performance status; Prostate; Second line treatment; Toxicity

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; BICALUTAMIDE; CABAZITAXEL; DOCETAXEL; GLYCOPROTEIN P; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; LOPERAMIDE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PREGABALIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANEMIA; ARTICLE; BINDING AFFINITY; BLOOD CELL COUNT; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MALE; METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SACRAL NERVE PAIN; THROMBOCYTOPENIA; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT;

EID: 80051703587     PISSN: 18759742     EISSN: 18759750     Source Type: Journal    
DOI: 10.1016/j.bjmsu.2011.05.004     Document Type: Article

References (14)

1. Cancer Research UK. Prostate cancer-UK incidence statistics. [accessed April, 2011]. http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/.
2. National Institute for Health and Clinical Excellence. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. (Technology Appraisal 101). Costing template. NICE. ; 2006 [accessed April, 2011]. http://www.nice.org.uk/nicemedia/live/11578/33354/33354.xls.
3. Tollefson M., Magera J., Sebo T., Cohen J., Drauch A., Maier J., et al. Raman spectral imaging of prostate cancer: can Raman molecular imaging be used to augment standard histopathology?. BJU Int 2010, 106:484-488.
4. National Institute for Health and Clinical Excellence. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. (Technology Appraisal 101). NICE. ; 2006 [accessed April, 2011]. http://www.nice.org.uk/nicemedia/pdf/TA101guidance.pdf.
5. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
6. Bahl A., Persad R. Metastatic castrate-resistant prostate cancer: New landscape, new challenges. Br J Med Surg Urol 2011, 4(S1):S9-S13.
7. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.-P., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
8. Pivot X., Koralewski P., Hidalgo J.L., Chan A., Gonçxalves A., Schwartsmann G., et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008, 19:1547-1552.
9. Mathew P., Dipaola R. Taxane refractory prostate cancer. J Urol 2007, 178:S36-41.
10. European Medicines Agency. Assessment report for Jevtana (cabazitaxel). Procedure no.: EMEA/H/C/002018. CHMP. ; 2011 [accessed April, 2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002018/WC500104766.pdf.
11. Mita A.C., Denis L.J., Rowinsky E.K., de Bono J.S., Goetz A.D., Ochoa L., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009, 15:723-730.
12. de Bono J.S., Sartor O. Cabazitaxel for castration-resistant prostate cancer - authors' reply. Lancet 2011, 377:122-123.
13. Lydon A. Cabazitaxel side effects: Prevention and management. Br J Med Surg Urol 2011, 4(S1):S21-S27.
14. de Bono J.S., Logothetis C.J., Fizazi K., North S., Chu L., Chi K.N., et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Presented at ESMO 2010, Abstract LBA5.